Mathematical modeling of HDV RNA, HBsAg, and ALT kinetics in patients with compensated cirrhosis: Insights from 96 Weeks of bulevirtide monotherapy.

Mhlanga A, Shekhtman L, Cotler SJ, Wasserman O, Degasperi E, Anolli MP, Uceda Renteria SC, Sambarino D, Borghi M, Perbellini R, Facchetti F, Callegaro A, Dahari H, Lampertico P

Open source

DOI
10.1016/j.antiviral.2026.106489
Published
2026 Sep
Container
Antiviral research
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.antiviral.2026.106489,
  title = {Mathematical modeling of HDV RNA, HBsAg, and ALT kinetics in patients with compensated cirrhosis: Insights from 96 Weeks of bulevirtide monotherapy.},
  author = {Mhlanga A and Shekhtman L and Cotler SJ and Wasserman O and Degasperi E and Anolli MP and Uceda Renteria SC and Sambarino D and Borghi M and Perbellini R and Facchetti F and Callegaro A and Dahari H and Lampertico P},
  year = {2026},
  journal = {Antiviral research},
  doi = {10.1016/j.antiviral.2026.106489},
  url = {https://doi.org/10.1016/j.antiviral.2026.106489}
}

RIS

TY  - JOUR
TI  - Mathematical modeling of HDV RNA, HBsAg, and ALT kinetics in patients with compensated cirrhosis: Insights from 96 Weeks of bulevirtide monotherapy.
AU  - Mhlanga A
AU  - Shekhtman L
AU  - Cotler SJ
AU  - Wasserman O
AU  - Degasperi E
AU  - Anolli MP
AU  - Uceda Renteria SC
AU  - Sambarino D
AU  - Borghi M
AU  - Perbellini R
AU  - Facchetti F
AU  - Callegaro A
AU  - Dahari H
AU  - Lampertico P
PY  - 2026
JO  - Antiviral research
DO  - 10.1016/j.antiviral.2026.106489
UR  - https://doi.org/10.1016/j.antiviral.2026.106489
ER  - 

APA

A, M., L, S., SJ, C., O, W., E, D., MP, A., SC, U. R., D, S., M, B., R, P., F, F., A, C., H, D., & P, L. (2026). Mathematical modeling of HDV RNA, HBsAg, and ALT kinetics in patients with compensated cirrhosis: Insights from 96 Weeks of bulevirtide monotherapy.. Antiviral research. https://doi.org/10.1016/j.antiviral.2026.106489

Source records